| Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women. (NCT06726850) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2024-10-14 |
| A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) (NCT06504394) | Merck Sharp & Dohme LLC | 2024-10-14 |
| Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC (NCT06827145) | National Cancer Center, China | 2024-10-14 |
| LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT06558799) | NovoCure GmbH | 2024-10-14 |
| FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer (NCT06636682) | Cellvax Therapeutics Inc | 2024-10-14 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection (NCT06585150) | Gilead Sciences | 2024-10-14 |
| Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL (NCT07234487) | St. Petersburg State Pavlov Medical University | 2024-10-14 |
| Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin (NCT06698965) | Shanghai Chest Hospital | 2024-10-13 |
| Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN (NCT06670352) | Haisco Pharmaceutical Group Co., Ltd. | 2024-10-12 |
| Thyme Honey for Management of Oral Lichen Planus (NCT06810752) | British University In Egypt | 2024-10-12 |
| Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations (NCT06640465) | OvationLab | 2024-10-12 |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (NCT05460000) | North Eastern German Society of Gynaecological Oncology | 2024-10-11 |
| Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial (NCT05337033) | University of Manitoba | 2024-10-11 |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia (NCT05849662) | Therapeutic Advances in Childhood Leukemia Consortium | 2024-10-11 |
| Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial (NCT06444269) | University of Texas Southwestern Medical Center | 2024-10-11 |
| Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection (NCT06434571) | University of Kansas Medical Center | 2024-10-11 |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations (NCT06581432) | Boehringer Ingelheim | 2024-10-11 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (NCT06388564) | Incyte Corporation | 2024-10-11 |
| A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults (NCT06625060) | Ipsen | 2024-10-10 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) (NCT06656962) | Renmin Hospital of Wuhan University | 2024-10-10 |
| A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma (NCT07599371) | The First Affiliated Hospital of Zhengzhou University | 2024-10-10 |
| Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease (NCT06923709) | Odense University Hospital | 2024-10-10 |
| Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. (NCT06600022) | Sinocelltech Ltd. | 2024-10-10 |
| Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (NCT06434103) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2024-10-10 |
| CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer (NCT06667050) | West China Hospital | 2024-10-10 |
| PK/PD of Digoxin in Infants With SVHD (NCT06613477) | Duke University | 2024-10-10 |
| Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (NCT05941520) | National Cancer Institute (NCI) | 2024-10-10 |
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis (NCT06619990) | Xencor, Inc. | 2024-10-10 |
| A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP) (NCT06646289) | Janssen Research & Development, LLC | 2024-10-10 |
| Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial (NCT06240754) | Washington University School of Medicine | 2024-10-10 |
| A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus (NCT06535412) | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 2024-10-10 |
| A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (NCT06522828) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2024-10-10 |
| Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy (NCT06377930) | Rapport Therapeutics Inc. | 2024-10-10 |
| Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) (NCT06434350) | M.D. Anderson Cancer Center | 2024-10-10 |
| A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients (NCT06557174) | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 2024-10-10 |
| Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities (NCT06399029) | University of Zurich | 2024-10-10 |
| Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma (NCT06348264) | Peking University First Hospital | 2024-10-10 |
| Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis (NCT06418594) | Beijing 302 Hospital | 2024-10-10 |
| Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (NCT07099222) | University of Arizona | 2024-10-10 |
| Cross-linked Hyaluronic Acid/dextranomer for the Treatment of Stress Urinary Incontinence (NCT06606613) | Izmir Bakircay University | 2024-10-10 |
| Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine (NCT06603623) | Biohaven Therapeutics Ltd. | 2024-10-10 |
| A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (NCT06598943) | Eli Lilly and Company | 2024-10-10 |
| The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. (NCT06600412) | River 3 Renal Corp. | 2024-10-10 |
| Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries (NCT06424834) | Stanford University | 2024-10-10 |
| Tissue Therapy of Transsphincteric Anal Fistula (NCT06303752) | University of Southern Denmark | 2024-10-09 |
| QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC (NCT06786026) | Fudan University | 2024-10-09 |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis (NCT06470048) | Novartis Pharmaceuticals | 2024-10-09 |
| Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) (NCT06577194) | The First Affiliated Hospital with Nanjing Medical University | 2024-10-09 |
| Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) (NCT07236476) | Luye Pharma Group Ltd. | 2024-10-09 |
| Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies (NCT06444880) | M.D. Anderson Cancer Center | 2024-10-09 |
| Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease (NCT06598631) | Eli Lilly and Company | 2024-10-09 |
| Pancreatic Cancer Diagnosis With FAPI-PET Imaging (NCT07098598) | Turku University Hospital | 2024-10-09 |
| Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (NCT06419179) | University of Cologne | 2024-10-09 |
| JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) (NCT06675422) | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2024-10-09 |
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia (NCT06525636) | Kyowa Kirin Co., Ltd. | 2024-10-09 |
| A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma (NCT06367075) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2024-10-09 |
| Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC (NCT06088771) | Icahn School of Medicine at Mount Sinai | 2024-10-09 |
| Study of LM-299 in Subjects Advanced Malignant Tumors (NCT06650566) | LaNova Medicines Limited | 2024-10-09 |
| Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (NCT06511050) | Icahn School of Medicine at Mount Sinai | 2024-10-09 |
| A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight (NCT06712836) | Pfizer | 2024-10-09 |
| Colon Cancer Diagnosis With FAPI-PET Imaging (NCT07272772) | Turku University Hospital | 2024-10-09 |
| Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma (NCT06014827) | City of Hope Medical Center | 2024-10-09 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma (NCT05996185) | Yale University | 2024-10-09 |
| Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) (NCT06682195) | First Affiliated Hospital of Zhejiang University | 2024-10-09 |
| Cardamom and Topical Roseomonas in Atopic Dermatitis (NCT06096857) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-10-09 |
| TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension (NCT06646198) | Fei Gao | 2024-10-08 |
| Prednisolone Acetate Eye Drops for Pain Intervention in Second Eye Cataract Surgery (NCT06614348) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2024-10-08 |
| Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity (NCT06579092) | AstraZeneca | 2024-10-08 |
| Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. (NCT06579105) | AstraZeneca | 2024-10-08 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma (NCT06102525) | Rznomics, Inc. | 2024-10-08 |
| A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection (NCT06672055) | Vaxart | 2024-10-08 |
| The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation (NCT06561880) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-08 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT05726682) | Sanofi | 2024-10-08 |
| Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (NCT06599216) | Harbin Medical University | 2024-10-08 |
| Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity (NCT06464939) | HysensBio Co., Ltd | 2024-10-08 |
| Local Injection and Systemic Therapy in the Treatment of NSCLC. (NCT06618391) | Henan Cancer Hospital | 2024-10-08 |
| Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma (NCT07364786) | Peter Siesjö | 2024-10-07 |
| Use of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of PIP Joint Osteoarthritis (NCT06034262) | TBF Genie Tissulaire | 2024-10-07 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. (NCT07155499) | AO GENERIUM | 2024-10-07 |
| Pilot Study of Reduced Venetoclax Exposure (NCT07163793) | Northwell Health | 2024-10-07 |
| The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults (NCT06027554) | UConn Health | 2024-10-07 |
| A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine (NCT06602479) | AbbVie | 2024-10-07 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors (NCT06631079) | NEC Bio B.V | 2024-10-07 |
| Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) (NCT06513312) | Gilead Sciences | 2024-10-07 |
| Early Intervention for Premyopic Children (NCT06200194) | National Yang Ming Chiao Tung University Hospital | 2024-10-06 |
| Tislelizumab with Azacitidine in the Treatment of R/R AML (NCT06586099) | Institute of Hematology & Blood Diseases Hospital, China | 2024-10-05 |
| Clinical and Radio-graphic Evaluation of Non-staining Bio-active Bio-ceramic (Neo MTA 2) in Revascularization (NCT06637761) | Cairo University | 2024-10-05 |
| A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors (NCT06605222) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-10-04 |
| Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG (NCT06690814) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2024-10-04 |
| Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet (NCT06369571) | Johns Hopkins University | 2024-10-04 |
| ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs (NCT06615505) | VIVEX Biologics, Inc. | 2024-10-04 |
| A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants (NCT06625671) | DualityBio Inc. | 2024-10-04 |
| Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) (NCT05947955) | BioAegis Therapeutics Inc. | 2024-10-03 |
| Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis (NCT06686472) | Telios Pharma, Inc. | 2024-10-03 |
| Can PLIA Reduce Early Post-operative Pain After PAO Surgery? (NCT06519955) | Michael C Willey | 2024-10-03 |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) (NCT06656416) | Alto Neuroscience | 2024-10-02 |
| A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas (NCT06490757) | Assistance Publique - Hôpitaux de Paris | 2024-10-02 |
| ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT06351644) | Adriana Rossi | 2024-10-02 |
| A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 (NCT06616766) | Yuhan Corporation | 2024-10-02 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial (NCT06541249) | Icahn School of Medicine at Mount Sinai | 2024-10-02 |